Chief Technology Officer Paul Talmo of TELA Bio Inc (TELA, Financial) purchased 22,222 shares of the company on October 24, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 91,082 shares of TELA Bio Inc.
TELA Bio Inc is a company that focuses on the development and marketing of a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a broad portfolio of products that are used in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
Over the past year, Paul Talmo has engaged in the purchase of 22,222 shares and has not sold any shares. The insider transaction history for TELA Bio Inc shows a pattern of more insider buying than selling, with 7 insider buys and only 1 insider sell over the past year.
Shares of TELA Bio Inc were trading at $2.25 on the day of the insider's recent purchase. The company has a market cap of $63.763 million.
According to the GF Value, the intrinsic value of TELA Bio Inc is estimated at $10.56 per share, which suggests that the stock is currently undervalued with a price-to-GF-Value ratio of 0.21. This valuation indicates a "Possible Value Trap, Think Twice" status, urging investors to be cautious.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business results.
This insider buying activity could be a signal to review the company's stock, especially considering the current valuation metrics and recent insider transactions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
